SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-089281
Filing Date
2024-08-01
Accepted
2024-08-01 16:10:10
Documents
13
Period of Report
2024-08-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atha-20240801.htm   iXBRL 8-K 46481
2 EX-99.1 atha-ex99_1.htm EX-99.1 118953
3 GRAPHIC img247042425_0.jpg GRAPHIC 17633
  Complete submission text file 0000950170-24-089281.txt   320872

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atha-20240801.xsd EX-101.SCH 26990
15 EXTRACTED XBRL INSTANCE DOCUMENT atha-20240801_htm.xml XML 4888
Mailing Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011
Business Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011 (425) 620-8501
Athira Pharma, Inc. (Filer) CIK: 0001620463 (see all company filings)

IRS No.: 453368487 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39503 | Film No.: 241166711
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)